valsartan
Diagnosing the drug supply: Exposing the bad practice of manufacturers in the developing world
July 22, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cipla, Contamination, FDA, India, chin, compliance, manufacturing, pharma, regulation, valsartan
The world needs cheap generic drugs and Indian manufacturers offer a steady supply. However the quality of generics has been …
FDA approve valsartan generic after shortages of supply
March 13, 2019Manufacturing and Production, Research and Development FDA, blood pressure drugs, cardiovascular, generic, valsartan
The FDA has approved a new generic version of blood pressure drug valsartan. The approval comes amid shortages in supply …
MHRA issues recall of irbesartan blood pressure meds over carcinogen contamination concerns
January 4, 2019Manufacturing and Production, Medical Communications MHRA, irbesartan, pharma, sartan, valsartan
Following a number of recalls issued in the US and Europe in the latter half of 2018 for the blood …
FDA expands list of valsartan recalls
August 9, 2018Medical Communications China, FDA, US, heart medication, recall, valsartan
The US Food and Drug Administration (FDA) has expanded a list of products containing valsartan that are to be recalled. …
EMA issues global recall of heart drugs over cancer risk contamination
July 10, 2018Manufacturing and Production EMA, Europe, heart disease, pharma, valsartan
Several drugs designed for the treatment of high blood pressure and heart conditions have been recalled across Europe over fears …
FDA approves Allergan hypertension fixed-dose combo, Byvalson
June 7, 2016Manufacturing and Production, Research and Development, Sales and Marketing Allergan, FDA, US, angiotensin ii, approval, beta blocker, byvalson, hypertension, nebivolol, valsartan
Allergan has announced that the US Food and Drug Administration (FDA) has approved its fixed-dose combination, Byvalson (nebivolol and valsartan), …
Novartis sales below forecast in ‘transformative’ year
January 28, 2015Sales and Marketing Diovan, Exforge, Gleevec, Jimenez, Novartis, amlodipine, q4, valsartan
Novartis’ fourth quarter sales have faded slightly as growth in pharmaceuticals is beaten back by generic competition, and the firm …
Novartis heart drug sees stellar results
September 1, 2014Sales and Marketing Diovan, LCZ696, Novartis, failure, heart, valsartan
Novartis’ new heart pill has produced stellar results in helping patients with heart failure live longer, making it the first …
Novartis faces data fraud charges in Japan
July 3, 2014Medical Communications, Sales and Marketing Diovan, Japan, Novartis, data, fraud, heart, valsartan
Novartis is facing criminal charges in Japan over the alleged falsifying of data for its once big-selling heart drug Diovan. …
Ranbaxy’s Diovan copycat approved in US
June 27, 2014Manufacturing and Production, Sales and Marketing Diovan, FDA, Novartis, Ranbaxy, blood pressure, sun pharmaceuticals, valsartan
Ranbaxy has won approval for its copycat form of Novartis’ blockbuster blood pressure drug Diovan, as the Swiss firm finally …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
